Baird Medical Investment Holdings Limited
BDMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.80 | 0.00 | -0.03 | -0.06 |
| FCF Yield | -4.72% | -4.50% | -8.48% | 5.46% |
| EV / EBITDA | 13.12 | 6.96 | 4.31 | 5.00 |
| Quality | ||||
| ROIC | 22.59% | 21.66% | 36.10% | 51.21% |
| Gross Margin | 88.16% | 86.56% | 79.90% | 83.61% |
| Cash Conversion Ratio | -0.50 | -0.10 | 0.04 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.82% | 4.30% | 24.65% | 31.43% |
| Free Cash Flow Growth | -150.56% | 33.10% | -241.39% | 18.94% |
| Safety | ||||
| Net Debt / EBITDA | 1.11 | 0.65 | 0.35 | -0.01 |
| Interest Coverage | 26.55 | 41.73 | 45.55 | 77.42 |
| Efficiency | ||||
| Inventory Turnover | 3.38 | 3.70 | 5.45 | 1.49 |
| Cash Conversion Cycle | 462.69 | 416.57 | 313.32 | 382.01 |